- Home
- PRAX
as 11-13-2025 3:41pm EST
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.0B | IPO Year: | 2020 |
| Target Price: | $212.42 | AVG Volume (30 days): | 978.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.70 - $206.71 | Next Earning Date: | 11-05-2025 |
| Revenue: | $7,463,000 | Revenue Growth: | 364.98% |
| Revenue Growth (this year): | -98.99% | Revenue Growth (next year): | 44.43% |
Stock Insider Trading Activity of Praxis Precision Medicines Inc. (PRAX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Adage Capital Management, L.P. | PRAX | 10% Owner | Oct 16 '25 | Sell | $111.24 | 313,910 | $33,198,123.57 | 2,361,485 |
Latest Praxis Precision Medicines Inc. News
PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing
MT Newswires
25 days ago
Wedbush Boosts Price Target on Praxis Precision Medicines to $73 From $33, Keeps Underperform Rating
Insider Monkey
a month ago
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results
Zacks
a month ago
Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains?
Yahoo Finance Video
a month ago
Tesla, Nvidia, Rigetti, Praxis: Trending Stocks
MT Newswires
a month ago
Deutsche Bank Boosts Price Target on Praxis Precision Medicines to $280 From $65, Keeps Buy Rating
MT Newswires
a month ago
Praxis Precision Medicines Prices $525 Million Share Offering
GlobeNewswire
a month ago
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
MT Newswires
a month ago
Praxis Precision Medicines Plans Public Offering
Compare PRAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.